Xponance’s Cytek Biosciences CTKB Stock Holding History

Xponance’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$51.3K	Buy	11,573 +980	+9%	+$4.18K	﹤0.01%	1784
2026 Q1	$46.3K	Buy	+10,593	New	+$50K	﹤0.01%	1636

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Xponance's CTKB Position: Q2 2026 in Review

Xponance increased its Cytek Biosciences (CTKB) stake by 9.3% in Q2 2026, buying an estimated $4.18K and bringing the position to 11,573 shares worth $51.3K. The position accounts for ﹤0.01% of the portfolio, ranked #1784.

Xponance first reported a position in CTKB in Q1 2026 and has held it in 2 quarters since. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Xponance held 11,573 shares of Cytek Biosciences worth $51.3K as of Q2 2026.
Xponance bought 980 Cytek Biosciences shares in Q2 2026, an estimated $4.18K.
Cytek Biosciences made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1784 holding.
Xponance first reported a position in Cytek Biosciences in Q1 2026 and has held it in 2 quarters since.
155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.